Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor.

previous PV diagnosis, achieved at least CCyR. In summary, in this larger cohort of CML patients compared with that studied by Makishima et al,1 we found 2.55% of cases presenting concomitant BCR/ABL rearrangement and JAK2V617F mutation, indicating that the simultaneous occurrence of these mutations is rare event but it is not a phoenix; however, while the pathophysiologic significance of this double mutated phenotype remains to be clarified, it seems clear that the predominant clinical phenotype is, in most cases, that of a typical BCR-ABL rearranged CML.